Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for heart failure patients with lung pressure problems

NCT ID NCT05737940

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called AZD3427 in 260 adults with heart failure and a type of high blood pressure in the lungs (pulmonary hypertension). The goal was to see if the drug could lower pressure in the lung's blood vessels after 24 weeks of treatment. Participants received either the drug or a placebo, and doctors measured changes using a heart catheterization procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

260 people

The number who actually took part.

Started

Apr 2023

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Participant must be ≥ 18 years of age inclusive. 2. Participants must have a pre-existing diagnosis of HF, NYHA function class (FC) II to IV, and a pre-existing diagnosis of PH-LHD or likely or intermediate probability of Pulmonary hypertension due to left heart disease (PH-LHD) as per 2022 Pulmonary hypertension due to left heart disease European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines. Participants must be on stable HF standard of care medication, including diuretics. 3. Participants must have a combination of echocardiographic parameters that show intermediate or high probability of PH as per 2022 ESC/ERS guidelines. 4. Participants must have an on-study elevated pulmonary artery pressure from RHC performed as per RHC manual provided by the Sponsor, at Screening Visit 2: 1. PAWP ≥ 15 mmHg 2. mPAP ≥ 20 mmHg 5. Minimum body weight of 45 kg (inclusive). 6. Capable and willing of giving signed informed consent. Exclusion Criteria 1. Diagnosis of PH in World Health Organization (WHO) Group 1, WHO Group 3, WHO Group 4, or WHO Group 5. 2. Historical or current evidence of a clinically significant disease or disorder. 3. Decompensated HF or hospitalisation due to decompensated HF. 4. Any contraindications to RHC. 5. History of hypersensitivity to SC injections or devices. 6. History of hypersensitivity to drugs with a similar chemical structure or class to AZD3427 or any component of AZD3427 drug product, or ongoing clinically important allergy/hypersensitivity. 7. Known lung disease with Forced expiratory volume in the first second (FEV1) \< 30% of predicted. 8. Congenital long QT syndrome. 9. Cardiac ventricular arrhythmia which requires treatment. Participants with atrial fibrillation or flutter and controlled ventricular rate are permitted. 10. History of or anticipated heart transplant or ventricular assist device implantation. 11. Any known planned (scheduled) highly invasive Cardiovascular (CV) procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter, valve repair/replacement, aortic aneurysm surgery, etc). 12. Participants who have previously received AZD3427.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Pulmonary hypertension (world health organization group 2)

Contacts and locations

Locations

  • Research Site

    Beverly Hills, California, 90211, United States

  • Research Site

    La Jolla, California, 92093, United States

  • Research Site

    New Haven, Connecticut, 06519, United States

  • Research Site

    Baltimore, Maryland, 21287, United States

  • Research Site

    St Louis, Missouri, 63136, United States

  • Research Site

    Omaha, Nebraska, 68198, United States

  • Research Site

    Rock Hill, South Carolina, 29732, United States

  • Research Site

    Linz, 4020, Austria

  • Research Site

    Vienna, 1100, Austria

  • Research Site

    Edmonton, Alberta, T6G 2E1, Canada

  • Research Site

    Vancouver, British Columbia, V6Z 1Y6, Canada

  • Research Site

    Halifax, Nova Scotia, B3H 3A7, Canada

  • Research Site

    London, Ontario, N6A 5A5, Canada

  • Research Site

    Ottawa, Ontario, K1Y 4W7, Canada

  • Research Site

    Toronto, Ontario, M5G 2N2, Canada

  • Research Site

    Montreal, Quebec, H1T 1C8, Canada

  • Research Site

    Beijing, 100034, China

  • Research Site

    Changsha, 430033, China

  • Research Site

    Guangzhou, 510100, China

  • Research Site

    Kunming, 650051, China

  • Research Site

    Prague, 10034, Czechia

  • Research Site

    Prague, 12808, Czechia

  • Research Site

    Prague, 140 21, Czechia

  • Research Site

    Aarhus, 8200, Denmark

  • Research Site

    Copenhagen, 2100, Denmark

  • Research Site

    Berlin, 13353, Germany

  • Research Site

    Cologne, 50937, Germany

  • Research Site

    Frankfurt, 60596, Germany

  • Research Site

    Jena, 07747, Germany

  • Research Site

    Brescia, 25123, Italy

  • Research Site

    Genoa, 16132, Italy

  • Research Site

    Marche, 60126, Italy

  • Research Site

    Milan, 20138, Italy

  • Research Site

    Milan, 20142, Italy

  • Research Site

    Trieste, 34149, Italy

  • Research Site

    Bunkyō City, 113-8603, Japan

  • Research Site

    Kasugai-shi, 487-0016, Japan

  • Research Site

    Kure-shi, 737-8505, Japan

  • Research Site

    Nagoya, 466-8560, Japan

  • Research Site

    Sapporo, 060-8648, Japan

  • Research Site

    Sunto-gun, 411-8611, Japan

  • Research Site

    Toyama, 930-0194, Japan

  • Research Site

    Deventer, 7416 SE, Netherlands

  • Research Site

    Heerlen, 6419 PC, Netherlands

  • Research Site

    Tilburg, 5022 GC, Netherlands

  • Research Site

    Bialystok, 15-276, Poland

  • Research Site

    Gdansk, 80-952, Poland

  • Research Site

    Krakow, 31-202, Poland

  • Research Site

    Warsaw, 02-005, Poland

  • Research Site

    Warsaw, 04-628, Poland

  • Research Site

    Wroclaw, 50-556, Poland

  • Research Site

    Majadahonda, 28222, Spain

  • Research Site

    Seville, 41009, Spain

  • Research Site

    Toledo, 45007, Spain

  • Research Site

    Valencia, 46026, Spain

  • Research Site

    Gothenburg, 413 45, Sweden

  • Research Site

    Huddinge, 141 57, Sweden

  • Research Site

    Cambridge, CB2 0AY, United Kingdom

  • Research Site

    Clydebank, G81 4DY, United Kingdom

  • Research Site

    London, SW3 6NP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.